


GRELL & ENCR

2025 Scientific Meeting Porto, Portugal

27-30
MAY



Figure 17. Stage distribution (n) of cervical cancer patients in Scotland, 2019 vs. 2020.



Source: Scottish Cancer Registry, Public Health Scotland (PHS) Cancer Incidence in Scotland to 2020; April 2022.

Stage shift in cervical cancer incidence: COVID or FIGO?

Lauren Schofield, Laura Lindsay, **Cheryl Denny**, Helen Storkey, David Morrison

Public Health Scotland & Macmillan Cancer Support




University
of Glasgow

MACMILLAN
CANCER SUPPORT


Cervical cancer and registration in Scotland


- Scotland – population 5.2 M
- National Health Service in Scotland
- Scottish Cancer Registry
 - *records from 1958*
- Cervical screening since 1988
 - *uptake ~70%*
- HPV vaccination
 - *since 2008*

Change in coding from FIGO 2014 (SCR) to FIGO 2018 (WOSCAN)




Change in coding from detailed FIGO 2014 (SCR) to FIGO 2018 3C only (WOSCAN)





Actual (solid lines) and estimated (dashed lines) EASR-adjusted incidence rate per 100,000 by stage.

Estimated EASR-adjusted rates based on poisson regression model (cases ~ stage + age group + offset(log(population))) using data 2014-2019.




Actual (solid lines) and estimated (dashed lines) and adjusted (dotted lines) easr-adjusted incidence rate by stage.

Estimated incidence based on poisson regression model (cases ~ stage + age group + offset(log(population))) using data between 2014-2019.

Adjusted incidence based on applying WOSCAN distribution of FIGO 2014 on 3C observations to other stages.

Arrows show the difference between actual and adjusted easr-adjusted incidence rate.



Actual (solid lines) and estimated (dashed lines) and adjusted (dotted lines) easr-adjusted incidence rate by stage.

Estimated incidence based on poisson regression model (cases ~ stage + age group + offset(log(population))) using data between 2014-2019.

Adjusted incidence based on applying WOSCAN distribution of FIGO 2014 on 3C observations to other stages.

Arrows show the difference between actual and adjusted easr-adjusted incidence rate.

Cervical cancer stage shift - COVID or FIGO?

Both:

- Stage I incidence truly fell

- Stage II decrease, Stage III increase explained by FIGO 2018 reclassification

All PBCRs changing to FIGO 2018 may see similar “stage shift”

General caution that stage reclassification may cause misclassification bias



Thank you to all clinicians who provided guidance:
Kevin Burton, Cameron Martin, Ann-Maree Kennedy, David Smith